| Ivermectin | Galderma | ||
| 1%; Cream, Topical |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
None | ||
|
Less Than 5
|
Less Than 5
|
||
| Indicated for the treatment of inflammatory lesions of rosacea | |||
|
Yes
| |||
| Soolantra | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ******* | ********* **** **** *********** | ********* **** **** *********** | ********* **** **** *********** | ********* **** **** *********** | ********* **** **** *********** | ********* **** **** *********** | ********* **** **** *********** | ********* **** **** *********** | ********* **** **** *********** | ********* **** **** *********** | ********* **** **** *********** | ********* **** **** *********** | ********* **** **** *********** |
| **** | ******* | **** *** | ******* | ******* | ******* | ******* | ******* | ******* | *** ** ** | *** ** ** | *** ** ** | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| **** | ***\ *** | *** **, **** | ******* ***** *** ** ** | ******** | ******** ** *** **, **** |
| ******* | **\ ** | *** **, **** | ******* | ******** ************ | *** ****** **** ******** |
| ***** ****** | **\ ** | **** **, **** | ******* | ******** | *** ****** *** **** |
Download ParaIV Report